Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The aim of this study was to explore the safety and efficacy of open-label tofacitinib following blinded treatment with adalimumab or tofacitinib for moderate to severe RA. METHODS: Analyses inc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Res Ther
Main Authors: Genovese, Mark C., van Vollenhoven, Ronald F., Wilkinson, Bethanie, Wang, Lisy, Zwillich, Samuel H., Gruben, David, Biswas, Pinaki, Riese, Richard, Takiya, Liza, Jones, Thomas V.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4918072/
https://ncbi.nlm.nih.gov/pubmed/27334658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-016-1049-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados